AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05299021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-point SAPB
Description: A high-frequency linear probe (6-13 MHz) of the ultrasound machine was used to identify the fifth rib in the midaxillary line. The anatomic landmarks of the block were identified: latissimus dorsi, serratus anterior, and the intercostal muscles in the fourth and fifth intercostal levels. After sterilization and draping, an 20-gauge needle was introduced craniocaudally using an in-plane technique. The needle tip was advanced, targeting the plane between the serratus anterior muscle and the fifth rib. Needle position was confirmed by injection of 1-to-2 mL of saline after negative aspiration.Under real-time visualization, total 30 mL of 0.375% ropivacaine and 0.5μ g/kg dexmedetomidine mixture will be injected.
Study NCT05116449 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of life questionnaires
Description: Different quality of life questionnaires : FACT-B, EORTC QLQ-C30, QIC, BRIEF COPE, HADS, QSSS-C
Study NCT05650723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib Pill
Description: 320 mg once per day by mouth
Study NCT05650723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Pill
Description: 400 mg once per day by mouth following the standard ramp-up schedule (20mg daily PO week 1, 50mg daily PO week 2, 100mg daily PO week 3, 200mg daily PO week 4, followed by 400mg PO daily week 5)
Study NCT05650723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab Injection
Description: 1000 mg IV given every 28 days
Study NCT06082921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beef Diet Intervention
Description: Participants will eat prepared meals including beef for 6 days. Participants will eat a habitual diet for 6 days prior to intervention.
Study NCT06082921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impossible Beef Diet Intervention
Description: Participants will eat prepared meals including impossible beef for one portion 6 days. Participants will eat a habitual diet for 6 days prior to intervention.
Study NCT05453175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interrupting sitting with Physical activity
Description: Participants will engage in three minutes of walking, five sit to stands and five calf raises every thirty minutes
Study NCT05768724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention diet
Description: The Resmena diet: It was characterized by a higher meal frequency, consisting of seven meals/d (including breakfast, lunch, dinner, and two snacks in the morning and two snacks in the afternoon), and by a different macronutrient distribution; 40% total energy value from CHO, 30% from proteins and 30% from lipids. This pattern tried to reinforce high n-3 polyunsaturated FA (n-3 PUFA) and high natural antioxidant food consumption and promoted low GL CHO intake as well as a high adherence to the Mediterranean diet. It also maintained a healthy FA profile and a cholesterol content of less than 300 mg/day.~* Daily meal plans were created according to the energy intake of the participants and sent to the participants via social media every week. Participants were asked to keep 3-day diet records to evaluate their compliance with the diet and were invited to the research center once a month to be checked.
Study NCT05768724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control diet
Description: Control diet: It was based on the American Heart Association (AHA) guidelines, including 3-5 meals per day, a macronutrient distribution of 55% total energy value from carbohydrates, 15% proteins, and 30% lipids, a healthy fatty acids (FA) profile and a cholesterol consumption lower than 300 mg/day.~- Daily meal plans were created according to the energy intake of the participants and sent to the participants via social media every week. Participants were asked to keep 3-day diet records to evaluate their compliance with the diet and were invited to the research center once a month to be checked
Study NCT05101135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JT-001
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT05101135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JT-001 Placebo
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT04062708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Preoperative Treatment:~* Non-squamous NSCLC: durvalumab 1125 mg, followed by pemetrexed 500 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~* Squamous NSCLC: durvalumab 1125 mg, followed by docetaxel 75 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~Adjuvant Therapy:~• 1-6 weeks after completion of radiotherapy, durvalumab 1500 mg IV every 4 weeks will be administered for 13 cycles.
Study NCT04062708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Patients will be re-evaluated following preoperative treatment to assess if patient is still medically fit to withstand surgery. Eligible patients will then undergo lobectomy, bilobectomy, sleeve lobectomy or other extended resection, or a pneumonectomy will be performed at the discretion of the attending thoracic surgeon.
Study NCT04062708 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 4-10 weeks after surgery, patients will receive 54 Gy of radiotherapy with single daily fractions.
Study NCT05134662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)
Study NCT05134662 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injected subcutaneously (SC)
Study NCT04804774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WW program modified for people with Type 2 diabetes
Description: This 6-month intervention includes the use of WW's mobile app, weekly virtual workshops, and private online community. The program involves: self-monitoring of weight, dietary intake, and physical activity; dietary changes; increasing physical activity; shift in mindset; and behavioral strategies to manage goals. Participants will set goals and weigh-in with a coach via virtual workshop weekly and be encouraged to use the app and private online community daily. The virtual workshop features a behavior change technique and enables the participant to practice it to support their goals. Participants are given a personalized food plan based on expert healthy eating guidelines, an activity plan to promote regular physical activity and techniques to help shift mindset for lasting change. The coach will help with goal setting, overcoming setbacks, and follow-up on progress toward goals weekly. Participants will be encouraged to participate in a private Facebook group for motivational support.
Study NCT05564741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine 1 MG/ML
Description: As proxy for hypotension we record amount of Norepinephrine given during the study time of 30 minutes
Study NCT05481216 — intervention group
Intervention type: OTHER
Intervention: COVID-19
Description: Diagnosed with COVID-19 infection
Study NCT05481216 — intervention group
Intervention type: OTHER
Intervention: HIV-1 infection
Description: Diagnosed with HIV-1 infection
Study NCT06383702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin sustained-release tablets
Description: Subjects will take pregabalin sustained-release tablets for the duration of 14 weeks. The dosage will include 165 mg daily (for the titration and the withdraw period) and 330 mg daily for the fixed-dose period.
Study NCT06383702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take placebo tablets for the duration of 14 weeks. The dosage will include 165 mg daily (for the titration and the withdraw period) and 330 mg daily for the fixed-dose period.
Study NCT06061432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic restoration of gastrointestinal continuity after Hartmann procedure
Description: EndoHARP is a new technique proposed to restore gastrointestinal continuity after the Hartmann's procedure. For EndoHARP, a fixed loop of the large intestine will be identified on endosonography after an echoendoscope is inserted into the rectal stump under endoscopic guidance. Then, using the set for inserting self-expandable metal transmural endoprosthesis (20 mm in diameter and 10 mm in length) with electrocautery (as in endoscopic gastroenterostomy), EUS-guided anastomosis of the rectal stump to the large intestine loop will be performed, allowing the natural passage of intestinal contents through the endoscopic anastomosis, restoring gastrointestinal continuity. The aim of leaving the self-expandable transmural endoprosthesis in the anastomosis is not only to maintain the patency of the intestinal anastomosis of at least 20 mm in diameter, but also to diminish the risk of endoscopic intestinal anastomotic leak by completely covering the prosthesis with a polymer layer.
Study NCT05590546 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention, only performing cross-sectional analysis of pooled data collected in previous studies
Study NCT06134804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC9V
Description: ExPEC9V will be administered as an IM injection.
Study NCT06134804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as an IM injection.
Study NCT06134804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HD quadrivalent influenza vaccine
Description: HD quadrivalent influenza vaccine will be administered as IM injection.
Study NCT05335109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: Xenon is injected into the body by inhalation in the form of xenon-oxygen mixtures, in which the concentration of xenon is 30%, and oxygen is 30%.~Xenon inhalation is carried out for 30 min daily for 3 days.
Study NCT05335109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen 30 %
Description: Oxygen-air mixture is injected into the body by inhalation. The oxygen concentration is 30%.~Inhalation of oxygen-air mixture is carried out for 30 min daily for 3 days
Study NCT05845476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient SOGI Self-Report
Description: EPIC® MyChart electronic health records messages will go to OSUCCC patients of pilot clinics who have incomplete SOGI data in their record and are enrolled in OSU MyChart. The message will request that patients complete SOGI data fields, with an explanation about why it is important for their health care, as well as links to document this information in their electronic health record (EHR).~Intervention Description:~EPIC® MyChart EHR messages will go to OSUCCC patients of pilot clinics who have incomplete SOGI data in their record and are enrolled in OSU MyChart. The message will request that patients complete SOGI data fields, with an explanation about why it is important for their health care, as well as links to document this information in their electronic health record.
Study NCT05845476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOGI Resource for Clinical Care Education (SORCE)
Description: SOGI Resource for Clinical Care Education (SORCE) training includes cultural competency and health education. SORCE training has been used on a smaller scale for two years at the OSUCCC-James, receiving excellent scores for presentation quality, knowledge gained, and presenter expertise. For the present study, SORCE training will be tailored based on results from Aim 1. The training curriculum includes didactic content (basics of the LGBTQ+ community, SOGI data collection for patient care and research, and social determinants of health for the LGBT community, 15 minutes), EHR SOGI data documentation demonstration (10 minutes), and open dialogue and role play (20 minutes). Trainees will be given EHR documentation tip sheets and laminated pocket cards with best practices for asking about SOGI, steps for documenting in the EHR, and additional resources.
Study NCT05845476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cancer Center Care Environment
Description: At the level of the OSUCCC, to include all inpatient and ambulatory spaces, the investigators will implement important measures aimed at changing culture and practice. This includes modification of policy and the EHR for SOGI documentation per National Academy of Science Engineering and Medicine recommendations, a multi-pronged approach to making the environment of care more visibly welcoming for SGM people, and leveraging existing diversity, equity, and inclusion structures and initiatives to shift culture at the cancer center.
Study NCT05633407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efgartigimod
Description: Efgartigimod IV 10 mg/kg infusion qw for 24 weeks. Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively
Study NCT05633407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Receive a matching placebo during weekly infusions during a treatment period of 24 weeks.~Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively
Study NCT06293300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BoNT A
Description: Participants with TBI-associated photophobia will come one time in person to the clinic and receive 35 Units of BoNT-A injected in 7 forehead sites (0.1 cc in each location).
Study NCT04244214 — intervention group
Intervention type: OTHER
Intervention: More Stamina
Description: More Stamina is a gamified task organization tool designed to help persons with MS manage their energy, to minimize the impact of fatigue in their day to day life.
Study NCT04774419 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated IMRT
Description: Treatment will consist of short-course, hypofractionated IMRT to deliver 25 Gy to the vaginal cuff and pelvic lymph nodes in 5 daily fractions over one week.
Study NCT05015998 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: Epidemiology of anemia associated with chronic kidney disease, rather than to evaluate specific drugs
Study NCT05481125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clareon IOL
Description: Alcon Clareon Aspheric Hydrophobic Acrylic IOL for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed. The lens is indicated for primary implantation in the capsular bag in the posterior chamber of the eye, replacing the natural crystalline lens. IOLs are implantable medical devices and are intended for long-term use over the lifetime of the pseudophakic subject.
Study NCT05012371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib
Description: Given PO
Study NCT05012371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT05012371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given PO
Study NCT05012371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05012371 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05155709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: siremadlin
Description: Siremadlin is a capsule taken orally once a day (QD) and comes in 10 mg, 20 mg and 30 mg strengths
Study NCT05155709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Venetoclax is a tablet taken orally once a day (QD) and comes in 10 mg, 50 mg and 100 mg strengths.
Study NCT05155709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Azacitidine is a powder for suspension for injection or powder for solution for infusion taken intravenously or subcutaneously according to standard local clinical practice
Study NCT05649306 — intervention group
Intervention type: OTHER
Intervention: Additional Education
Description: Study-Specific Patient Handouts, Treating-Provider led counseling, Women's Bladder Cancer Support Group, Women's Bladder Cancer Educational Series, and referrals for additional support services
Study NCT05649306 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Female Sexual Function Index, Demoralization Scale-II
Study NCT05649306 — intervention group
Intervention type: OTHER
Intervention: Attendance Diary
Description: Attendance Diaries for the Women's Bladder Cancer Support Group, Women's Bladder Cancer Educational Series, and additional educational and support services utilized
Study NCT05917977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collective Motivational Interviewing plus Education Materials
Description: The participants in the intervention group will receive IGD educational materials as well as four counseling sessions of CMI intervention.
Study NCT05917977 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group (Education Materials)
Description: The participants in the control group will receive IGD educational materials.
Study NCT05481125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clareon Toric IOL
Description: Clareon Toric Aspheric Hydrophobic Acrylic Toric IOL for the visual correction of aphakia with pre-existing corneal astigmatism in adult patients in whom a cataractous lens has been removed. The lens is indicated for primary implantation in the capsular bag in the posterior chamber of the eye, replacing the natural crystalline lens. IOLs are implantable medical devices and are intended for long-term use over the lifetime of the pseudophakic subject.
Study NCT05481125 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eyhance IOL
Description: TECNIS Eyhance IOL with TECNIS Simplicity Delivery System for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed by extracapsular cataract extraction. The lens is intended to be placed in the capsular bag. IOLs are implantable medical devices and are intended for long-term use over the lifetime of the pseudophakic subject.
Study NCT05481125 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eyhance Toric IOL
Description: TECNIS Eyhance Toric II IOL with TECNIS Simplicity Delivery System for the visual correction of aphakia and pre-existing corneal astigmatism of one diopter or greater in adult patients with or without presbyopia in whom a cataractous lens has been removed by phacoemulsification and who desire reduction in residual refractive cylinder. The lens is intended to be placed in the capsular bag. IOLs are implantable medical devices and are intended for long-term use over the lifetime of the pseudophakic subject.
Study NCT05481125 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification surgery
Description: Cataract removal by routine small incision phacoemulsification surgery
Study NCT05481125 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification surgery
Description: Cataract removal by routine small incision phacoemulsification surgery
Study NCT05379270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet soda
Description: Participants will be asked to drink 24 ounces of a commercially-available diet beverage sweetened with sucralose and acesulfame-potassium.
Study NCT05353348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose, recombinant human erythropoietin, ascorbic acid
Description: During the 1 week period following admission, 3 consecutive dosing regimens were administered, 200 mg of iron sucrose by intravenous infusion at 8am daily in combination with 150 IU/kg of recombinant human erythropoietin by subcutaneous injection and 2 g of ascorbic acid by intravenous infusion.
Study NCT05353348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: Treatment in accordance with measures routinely used by the surgeon's team to treat anemia including but not limited to (clinical observation, oral iron supplementation, intravenous iron supplementation, blood transfusion, or other measures) will be documented faithfully by the study team
Study NCT05996328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-delivered meals and short-term dietary counseling
Description: Home-delivered, low-sodium, nutritionally robust meals for 6 weeks plus two additional remotely delivered dietary counseling sessions in addition to the study-defined standard of care.
Study NCT05996328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study -defined standard of care
Description: study-defined standard of care consists of standardized dietary education and a single dietary counseling session shortly after discharge
Study NCT05869682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bright White Light Therapy
Description: Wear AYOpro BWL therapy
Study NCT05869682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Drug Therapy
Description: Receive SOC ADT combination therapy
Study NCT05869682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT05869682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05869682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05763784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tightrope
Description: Tightrope use special fiber and a set of metal buttons to fix diastasis of a joint.